Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
40 hedge funds and large institutions have $2.25M invested in Nymox Pharmaceutical Corp in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 11 closing their positions.
10% more capital invested
Capital invested by funds: $2.05M → $2.25M (+$201K)
5% less call options, than puts
Call options by funds: $35K | Put options by funds: $37K
7% less funds holding
Funds holding: 43 → 40 (-3)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$168K |
| 2 |
M
Murchinson
Toronto,
Ontario, Canada
|
+$118K |
| 3 |
DDC
DF Dent & Co
Baltimore,
Maryland
|
+$116K |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$71K |
| 5 |
WP
WMS Partners
Towson,
Maryland
|
+$64.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
-$132K |
| 2 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$54K |
| 3 |
Jane Street
New York
|
-$33K |
| 4 |
Millennium Management
New York
|
-$28K |
| 5 |
FTDI
First Trust Direct Indexing
Boston,
Massachusetts
|
-$15K |
NYMX Hedge Fund Activity: Q1 2022 in Review
40 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q1 2022, worth a combined $2.25M — up 9.8% from $2.05M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of NYMX and 8 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 3 added.
The largest buyer was Citigroup, opening a new position worth an estimated $168K. The largest seller was Ergoteles, exiting entirely with an estimated $132K sold.
- 40 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q1 2022, down from 43 in Q4 2021.
- Funds reported $2.25M of Nymox Pharmaceutical Corp stock for Q1 2022, up 9.8% quarter-over-quarter.
- 8 funds opened new Nymox Pharmaceutical Corp positions in Q1 2022 and 11 closed out, a net change of -3 holders.
- The largest Nymox Pharmaceutical Corp buyer in Q1 2022 was Citigroup, an estimated $168K added.
- The largest Nymox Pharmaceutical Corp seller in Q1 2022 was Ergoteles, an estimated $132K sold.
Based on aggregated 13F filings for Q1 2022.